Medical Ultrasound Imaging
Wednesday, 4 December 2024
 Info Sheets  Out- side     | 'Nycomed Amersham' Searchterm 'Nycomed Amersham' found in 3 articles 2 definitions [ • ] - 1 boolean [• ]Result Pages : •
From GE Healthcare;; Optison is the first 'second generation USCA' marketed in the US. Ultrasound contrast agents used during an ultrasound imaging procedure, enable more accurate diagnosis of the patient's heart condition. The application of Optison allows to image the endocardial borders of the heart, to see cardiac wall motion abnormalities and to guide the selection and monitoring of treatment. Optison represents a class of microbubbles with a shell formed by sonicating a solution of capsules filled with a perfluoropropane gas. The high molecular weight slows microbubble dissolution and prolongs the enhancement for several minutes. The human albumin-stabilized cavitation bubbles have a surface tension of 0.9 N/m and a surface dilatational viscosity 0.08 msP. 'August 06, 2001 Molecular Biosystems Inc., a subsidiary of Alliance Pharmaceutical Corp, announced the amendment of the Optison Product Rights Agreement (OPRA) dated May 9, 2000 with Mallinckrodt Inc, a unit of Tyco Healthcare. Optison, an intravenous ultrasound contrast agent, was developed by MBI and is being marketed by Mallinckrodt in the U.S. and Europe. Under the amended agreement, MBI will receive an immediate cash payment plus additional unspecified royalties for a two-year period. The amendment of OPRA coincides with an announcement by Nycomed Amersham Imaging that Nycomed and Mallinckrodt will terminate their joint commercialization and development agreement for ultrasound contrast agents, including Optison, effective Dec. 31, 2001. Effective Jan. 1, 2002, all selling and marketing activities will be resumed solely by Nycomed Amersham.'
Drug Information and Specification
RESEARCH NAME
FS069
DEVELOPER
INDICATION -
DEVELOPMENT STAGE LVO -
For sale APPLICATION
intravenous/oral
TYPE
AlbuminN-acetyltryptophan,Caprylic acid
CHARGE
Slight Negative
Octafluoropropane
MICROBUBBLE SIZE
93% < 10μm
PRESENTATION
Five 3ml vials
STORAGE
Refrigerate 2-8 °C
PREPARATION
Hand agitate
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information
TERRITORY
DISTRIBUTOR
USA, EU
•
EchoSeed™ consists of radioactive 125I (iodine-125) seeds/implants indicated for the treatment of prostate cancer with brachytherapy. The design of this second generation product, used in combination with ultrasound imaging, facilitates optimal placement. EchoSeed™ allows the physician to view both the prostate gland and the seeds during the course of the implant procedure. Nycomed Amersham. Source: PR Newswire - 06/04/01. •
EchoGen® is a fluorocarbon-based (dodecafluoropentane) third generation USCA. EchoGen® consists of microbubbles stabilized with surfactants in a phase shift colloid emulsion (perflenapent). EchoGen® requires no preparation, reconstitution, or refrigeration.
Perflenapent emulsion would represent a significant advance in contrast echocardiography caused by effective and long lasting opacification of the left ventricle and enhanced endocardial border delineation. The persistence of the contrast effect permits interrogation in multiple echocardiographic views, as well as the visualization and localization of myocardial perfusion deficits at rest by producing a negative contrast effect. October 12, 2000 Sonus Pharmaceuticals, Inc. announced a strategic decision to refocus the Company on the development of its drug delivery and blood substitute products. At the same time, Sonus has withdrawn the NDA (New Drug Application) and discontinued clinical activity for its ultrasound contrast product, EchoGen®. August 06, 2001 Sonus Pharmaceuticals, Inc. announced that it has entered into an agreement to sell its ultrasound contrast assets for $6.5 million to Amersham plc. As part of the agreement, Sonus has also assigned to Nycomed its interest in the ultrasound contrast patent license agreement entered into with Chugai Pharmaceutical Co. Ltd. and Molecular Biosystems Inc in January 2001.
Drug Information and Specification
RESEARCH NAME
QW3600
DEVELOPER
INDICATION -
DEVELOPMENT STAGE APPLICATION
Intravenous
TYPE
Microbubble
-
CHARGE
Negative
Dodecafluoropentane
MICROBUBBLE SIZE
-
PRESENTATION
-
STORAGE
Refrigerate 2−8 °C
PREPARATION
Finished product
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!  Further Reading: News & More:
Result Pages : | Share This Page     Look Ups |
Medical-Ultrasound-Imaging.com
former US-TIP.com
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology TIP • Medical-Ultrasound-Imaging
Copyright © 2008 - 2024 SoftWays. All rights reserved.
Terms of Use | Privacy Policy | Advertise With Us
former US-TIP.com
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology TIP • Medical-Ultrasound-Imaging
Copyright © 2008 - 2024 SoftWays. All rights reserved.
Terms of Use | Privacy Policy | Advertise With Us
[last update: 2023-11-06 01:42:00]